CIL 003
Alternative Names: CIL-003Latest Information Update: 13 Jun 2024
At a glance
- Originator Sanofi
- Developer Cilcare
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sensorineural hearing loss
Most Recent Events
- 10 Jun 2024 Cilcare and Shionogi agree to co-promote CIL 001 in world for hearing loss
- 29 May 2024 Cilcare has patent protection for CIL 003, before May 2024 (Cilcare website, May 2024)
- 29 May 2024 Preclinical trials in Sensorineural hearing loss in France (unspecified route), before May 2024 (Cilcare pipeline, May 2024)